Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given a consensus rating of “Hold” by the nine brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $8.24.

A number of equities analysts have recently commented on ZNTL shares. Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $1.51 on Tuesday. The stock’s 50-day moving average is $1.33 and its 200-day moving average is $2.00. The company has a market cap of $108.65 million, a price-to-earnings ratio of -0.61 and a beta of 1.61. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $8.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, hitting analysts’ consensus estimates of ($0.67). Research analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers acquired 21,000 shares of the company’s stock in a transaction on Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the acquisition, the director now directly owns 281,192 shares of the company’s stock, valued at $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Savant Capital LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $72,000. Ieq Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $46,000. Anfield Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock worth $392,000 after acquiring an additional 64,659 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Zentalis Pharmaceuticals by 22.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after acquiring an additional 91,152 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $68,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.